RFG Advisory LLC Purchases Shares of 5,266 Qiagen (NYSE:QGEN)

RFG Advisory LLC acquired a new position in shares of Qiagen (NYSE:QGEN) during the 4th quarter, Holdings Channel reports. The firm acquired 5,266 shares of the company’s stock, valued at approximately $234,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. GAMMA Investing LLC increased its position in Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares during the last quarter. Toronto Dominion Bank bought a new position in Qiagen during the second quarter worth $27,000. Massmutual Trust Co. FSB ADV increased its holdings in shares of Qiagen by 39.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Qiagen in the third quarter valued at about $53,000. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of Qiagen by 83.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company’s stock worth $70,000 after buying an additional 712 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 17th. Jefferies Financial Group reissued a “buy” rating and set a $54.00 price target (up from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a report on Monday, January 6th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.50.

Qiagen Trading Down 0.7 %

NYSE QGEN opened at $45.15 on Wednesday. The firm has a market capitalization of $10.30 billion, a PE ratio of 115.78, a price-to-earnings-growth ratio of 3.49 and a beta of 0.37. The business’s 50-day moving average price is $44.77 and its two-hundred day moving average price is $44.37. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 12 month low of $39.03 and a 12 month high of $47.93.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.